RenovoRx, Inc. (RNXT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. RenovoRx, Inc. is a commercial and clinical-stage life sciences company focused on the RenovoCath device, an FDA-cleared local drug delivery system. The company is commercializing RenovoCath as a standalone device for interventional radiologists and oncologists while advancing its lead drug-device combination candidate, IAG (intra-arterial gemcitabine), in a pivotal Phase III clinical trial (TIGeR-PaC) for locally advanced pancreatic cancer (LAPC).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $422,000 | $619,000 | $0 |
| Cost of Revenue | $152,000 | $246,000 | $0 |
| Gross Profit | $270,000 | $373,000 | $0 |
| Net Loss | $(2,895,000) | $(5,315,000) | $(3,465,000) |
| Operating Expenses | $2,948,000 | $6,161,000 | $5,510,000 |
| Cash and Equivalents (End of Period) | $12,314,000 (as of June 30, 2025) | ||
| Accumulated Deficit | $(55,534,000) (as of June 30, 2025) | ||
| Net Cash Used in Operating Activities | $(5,683,000) (YTD 2025) | ||
| Net Cash Provided by Financing Activities | $10,845,000 (YTD 2025) |
Material Changes vs. Prior Period
- Revenue Generation: The company recognized $422,000 in revenue for Q2 2025, compared to $0 in Q2 2024. This marks the second full quarter of commercial sales for the RenovoCath standalone device, driven by new customer orders and repeat business from academic and NCI-designated cancer centers.
- Financing Activity: In February 2025, the company completed an underwritten public offering, raising net proceeds of approximately $10.8 million. This significantly bolstered liquidity compared to the prior year period.
- Operating Expenses: Total operating expenses for the six months ended June 30, 2025, increased by 12% ($651,000) compared to the same period in 2024. This increase was driven by higher non-recurring engineering costs to scale manufacturing and increased headcount/benefits.
- Other Income/Expense: Net other income decreased significantly year-over-year due to a change in the fair value of the common stock warrant liability. In Q2 2025, this resulted in a $350,000 expense, whereas Q2 2024 showed a $507,000 gain.
Guidance, Outlook, and Risks
- Clinical Trial Progress: The Phase III TIGeR-PaC trial for IAG has randomized 95 patients with 61 events as of August 12, 2025. The independent Data Monitoring Committee (DMC) recently recommended continuing the trial following the second interim analysis. The company expects to complete enrollment in late 2025 or early 2026.
- Commercial Outlook: Management expects to grow RenovoCath revenue over time. They recently launched the PanTheR post-marketing registry study to evaluate RenovoCath for solid tumors. The company plans to hire a small number of sales personnel in the second half of 2025 to support commercial expansion.
- Liquidity: With $12.3 million in cash, management believes funds are sufficient to operate for at least the next 12 months. However, the company expects to continue incurring losses and will likely require additional capital to fund future operations and development.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective due to previously identified material weaknesses in internal control over financial reporting. These weaknesses relate to a lack of formal accounting policies, insufficient staffing, and inadequate segregation of duties. Remediation efforts are underway.
- Risk Factors: Key risks include the failure of the TIGeR-PaC trial, inability to secure additional financing, uncertainties in revenue recognition for the new commercial model, and reliance on third-party manufacturers.
Investor Verification Checklist
- Verify the sustainability of RenovoCath standalone revenue growth and the timeline for profitability.
- Monitor the final results of the Phase III TIGeR-PaC trial and the DMC's final recommendation.
- Assess the progress of remediation for the material weaknesses in internal controls over financial reporting.
- Review the company's ability to raise additional capital given the high burn rate and accumulated deficit.
- Confirm the status of the PanTheR registry study enrollment and its potential impact on future indications.